Cantargia
Develops antibody therapies targeting IL1RAP for cancer and inflammatory diseases.
CANTA | ST
Overview
Corporate Details
- ISIN(s):
- SE0006371126 (+3 more)
- LEI:
- 549300GKWRT7RXI4VS85
- Country:
- Sweden
- Address:
- Scheelevägen 27, 223 63 Lund
- Website:
- https://cantargia.com/en/
- Sector:
- Manufacturing
Description
Cantargia is a biotechnology company that develops antibody-based therapies targeting the interleukin-1 receptor accessory protein (IL1RAP). This protein is involved in signaling pathways that can drive cancer and inflammatory diseases. The company's lead asset, nadunolimab (CAN04), is a clinical-stage antibody under investigation for the treatment of various forms of cancer, including pancreatic cancer. Cantargia also developed the CAN10 program, an antibody targeting IL1RAP for autoimmune and inflammatory conditions, which was acquired by Otsuka Pharmaceutical.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-30 20:10 |
Cantargia has completed a directed share issue of approximately SEK 59 million
|
English | 93.9 KB | ||
| 2023-10-30 20:10 |
Cantargia har genomfört en riktad nyemission om cirka 59 miljoner kronor
|
Swedish | 93.7 KB | ||
| 2023-10-21 07:30 |
Cantargia: ESMO 2023 presentation of nadunolimab phase I clinical interim data …
|
English | 90.6 KB | ||
| 2023-10-21 07:30 |
Cantargia: ESMO 2023-presentation av kliniska fas I-interimsdata för nadunolima…
|
Swedish | 91.3 KB | ||
| 2023-10-04 14:35 |
Cantargia: Third party appeals recent EPO decision to maintain granted Cantargi…
|
English | 84.7 KB | ||
| 2023-10-04 14:35 |
Cantargia: Tredje part överklagar beslut av europeiska patentverket (EPO) att u…
|
Swedish | 86.4 KB | ||
| 2023-09-27 23:30 |
Cantargia presents new clinical data further supporting nadunolimab’s antitumor…
|
English | 96.4 KB | ||
| 2023-09-27 23:30 |
Cantargia presenterar nya kliniska data som styrker nadunolimabs antitumöraktiv…
|
Swedish | 97.4 KB | ||
| 2023-09-20 12:00 |
Cantargia: New preclinical data on nadunolimab potential to enhance anti-tumor …
|
English | 87.4 KB | ||
| 2023-09-20 12:00 |
Cantargia: Nya prekliniska data på nadunolimabs potential att förstärka antitum…
|
Swedish | 88.2 KB | ||
| 2023-09-18 15:02 | English | 36.0 KB | |||
| 2023-09-18 07:30 |
Cantargia meddelar ny klinisk studie med nadunolimab inom leukemi finansierad a…
|
Swedish | 86.6 KB | ||
| 2023-09-06 12:47 | English | 36.0 KB | |||
| 2023-09-06 08:00 |
Cantargia: FDA beviljar särläkemedelsstatus (Orphan Drug Designation) till CAN1…
|
Swedish | 84.1 KB | ||
| 2023-09-05 13:20 | English | 36.0 KB |
Automate Your Workflow. Get a real-time feed of all Cantargia filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Cantargia
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Cantargia via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-03-19 | Nedjad Losic | Other | Buy | 21,375 | 33,131.25 SEK |
| 2025-01-02 | Antonius Franciscus Berkien | Other | Other | 21,621 | 39,998.85 SEK |
| 2024-12-20 | Göran Forsberg | Other | Other | 152,206 | 281,581.10 SEK |
| 2024-12-20 | Nedjad Losic | Other | Other | 12,875 | 23,818.75 SEK |
| 2024-12-09 | Antonius Franciscus Berkien | Other | Buy | 3,741 | 6,733.80 SEK |
| 2023-01-19 | Nedjad Losic | Other | Buy | 3,918 | 29,110.74 SEK |
| 2023-01-17 | Göran Forsberg | Other | Buy | 17,000 | 140,250.00 SEK |
| 2023-01-17 | Bengt Jöndell | Other | Buy | 6,500 | 54,665.00 SEK |
| 2022-07-28 | Göran Forsberg | Other | Other | 91,765 | 344,118.75 SEK |
| 2022-07-28 | Thoas Fioretos | Other | Other | 78,400 | 294,000.00 SEK |
Peer Companies
